Zacks Investment Research upgraded shares of DELCATH SYS INC (DCTH) from NEUTRAL to OUTPERFORM on January 09, 2013, with a target price of $1.40.
Delcath Systems, Inc. has developed a system, the Delcath system, to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on DELCATH SYS INC (DCTH),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment